Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2011

View Archived Issues

Irbesartan/amlodipine besilate combination lowers blood pressure uncontrolled by either agent alone

Terutroban not more protective than aspirin in PERFORM trial in patients with prior stroke

Candesartan is not beneficial as blood pressure-lowering therapy in SCAST trial

Phase II data on ENMD-2076 in ovarian cancer reported at ASCO meeting

Scientists at Lytix Biopharma generate novel antimicrobials

Azanin tablets are approved for additional indications in Japan

Opexa meets with Health Canada regarding planned trials of Tovaxin in MS

NI-1201 targets classic and trans IL-6 signaling pathways, showing promise to treat inflammation

CYT-387 improves anemia in phase I/II trial in myelofibrosis

New GCS activators designed by Auspex Pharmaceuticals

Bristol-Myers Squibb claims new nicotinic acetylcholine alpha7 receptor agonists

Takeda presents novel tachykinin NK2 receptor antagonists

Tibotec discloses new inhibitors of HCV replication

BioDelivery Sciences provides update on modified REMS program for Onsolis

ImmunoCellular Therapeutics to use BioWa's Potelligent technology for anticancer antibodies

ACE-011 enters phase II/III trial to treat chemotherapy-induced anemia in patients with NSCLC

Adeona reports results from analysis of phase I/II data on reaZin in Alzheimer's disease

Morphotek begins phase II MORAb-004 study in melanoma

Health Canada approves AstraZeneca Canada's Brilinta

Phase III Get-Goal-L trial of lixisenatide in type 2 diabetes meets primary endpoint

Algeta to stop phase III ALSYMPCA trial of Alpharadin based on statistically significant efficacy

Orexigen Therapeutics to appeal FDA's decision regarding Contrave NDA

FDA accepts for review Sunovion's NDA for Nycomed's ciclesonide HFA nasal aerosol

Novartis gains approval in Europe for new indication of Lucentis

Ligand grants worldwide license to Captisol-enabled clopidogrel to The Medicines Company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...